<DOC>
	<DOCNO>NCT00793572</DOCNO>
	<brief_summary>This phase II trial study side-effects anti-cancer effect give autologous syngeneic stem cell transplant follow allogeneic donor stem cell transplant bortezomib . Patients treat trial newly diagnose high-risk , relapse , refractory multiple myeloma ( MM ) . Giving chemotherapy autologous stem cell transplant slow stop growth cancer cell prevent divide kill . Stem cell harvest earlier patient 's blood frozen return patient replace blood-forming cell destroy chemotherapy . Giving chemotherapy total-body irradiation allogeneic donor stem cell transplant also prevent patient 's immune system reject donor 's stem cell . Undergoing autologous syngeneic stem cell transplantation follow allogeneic donor stem cell transplant bortezomib may overall effective kill cancer cell .</brief_summary>
	<brief_title>Autologous Syngeneic Stem Cell Transplant Followed Donor Stem Cell Transplant Bortezomib Treating Patients With Newly Diagnosed High-Risk , Relapsed , Refractory Multiple Myeloma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I. Progression-free survival ( PFS ) 2 year autograft ( = &lt; 50 % historic control ) . SECONDARY OBJECTIVES : I . Overall survival ( OS ) 2 year autograft . II . Non-relapse mortality ( NRM ) 200 day 1 year allograft . III . Incidence grade II-IV acute graft-versus-host-disease ( GVHD ) chronic extensive GVHD . IV . Safety bortezomib maintenance therapy stem cell transplantation . OUTLINE : PERIPHERAL BLOOD STEM CELL ( PBSC ) MOBILIZATION : Patients undergo PBSC mobilization collection use preferred regimen participate institution . CONDITIONING CHEMOTHERAPY AND AUTOLOGOUS OR SYNGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION ( HSCT ) : Patients receive high-dose melphalan intravenously ( IV ) day -2 follow autologous syngeneic HSCT day 0 . NON-MYELOABLATIVE ALLOGENEIC HSCT : Beginning 40-180 day autologous HSCT , patient receive 1 follow regimen : 1 . HLA-IDENTICAL RELATED DONOR : Patients receive cyclosporine IV orally ( PO ) twice daily ( BID ) start day -3 56 , taper day 180 . Patients undergo total-body irradiation ( TBI ) non-myeloablative allogeneic HSCT day 0 . Four six hour completion allogeneic HSCT , patient receive mycophenolate mofetil ( MMF ) PO BID day 0-27 . 2 . HLA-UNRELATED DONOR : Patients receive fludarabine phosphate IV day -4 -2 . Patients also receive cyclosporine IV PO BID start day -3 100 taper day 180 . Patients undergo TBI non-myeloablative allogeneic HSCT day 0 . Four six hour completion allogeneic HSCT , patient receive MMF PO thrice daily ( TID ) day 0-27 BID day 27-40 taper MMF day 40-96 . MAINTENANCE THERAPY : Beginning 60-120 day allogeneic HSCT , patient receive bortezomib subcutaneously ( SC ) day 1 4 14-day cycle 9 month 18 cycle absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 3 month 1 year annually 5 year .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Mechlorethamine</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Nitrogen Mustard Compounds</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<criteria>Newly diagnose patient must receive induction therapy ( e.g. , vincristine , doxorubicin , dexamethasone [ VAD ] , thalidomide/dexamethasone ) minimum 4 cycle Must capacity give informed consent Must human leukocyte antigen ( HLA ) genotypically identical sibling phenotypically match relative , minimum , high likelihood identify HLAmatched unrelated donor ; determination availability suitable unrelated donor may base WorldBook search In addition , patient must meet least one criterion AI ( AG time diagnosis preautograft ) : A ) Any abnormal karyotype metaphase analysis except isolate ( 11,14 ) constitutional cytogenetic abnormality B ) Fluorescence situ hybridization ( FISH ) translocation 4 ; 14 C ) FISH translocation 14 ; 16 D ) FISH deletion 17p E ) Beta2microglobulin &gt; 5.5 mg/L F ) Cytogenetic hypodiploidy G ) Plasmablastic morphology ( &gt; = 2 % ) DONOR : HLA genotypically identical sibling phenotypically match relative OR DONOR : HLA phenotypically match unrelated donor ( accord Standard Practice HLA match criterion , Grade # 2.1 ) Matched HLAA , B , C , DRB1 , DQB1 alleles high resolution typing . Only single allele disparity allow HLAA , B , C define high resolution type Recurrent nonresponsive ( less partial response [ PR ] ) MM least two different line conventional chemotherapy Progressive MM previous autograft Life expectancy severely limited disease malignancy Seropositive human immunodeficiency virus ( HIV ) Females pregnant breastfeed Fertile men woman unwilling use contraceptive technique 12 month follow treatment Patients active nonhematological malignancy ( except nonmelanoma skin cancer ) nonhematological malignancy ( except nonmelanoma skin cancer ) render evidence disease , great 20 % chance disease recurrence within 5 year ; exclusion apply patient nonhematologic malignancy require therapy Patients fungal infection radiological progression receipt amphotericin B active triazole great 1 month Patients follow organ dysfunction : Symptomatic coronary artery disease ejection fraction &lt; 40 % cardiac failure require therapy ; myocardial infarction within 6 month prior enrollment New York Heart Association ( NYHA ) class III IV heart failure , uncontrolled angina , severe uncontrolled ventricular arrhythmia , electrocardiographic evidence acute ischemia active conduction system abnormalities Ejection fraction require patient history anthracyclines history cardiac disease Diffusing lung capacity carbon monoxide ( DLCO ) &lt; 50 % , forced expiratory volume 1 second ( FEV ) &lt; 50 % and/or receive supplementary continuous oxygen ; Fred Hutchinson Cancer Research Center ( FHCRC ) principle investigator ( PI ) study must approve enrollment patient pulmonary nodule Liver function abnormality : Patient clinical laboratory evidence liver disease evaluate cause liver disease , clinical severity term liver function , bridge fibrosis , degree portal hypertension ; patient exclude he/she find fulminant liver failure ; cirrhosis liver evidence portal hypertension ; alcoholic hepatitis ; esophageal varix ; history bleed esophageal varix ; hepatic encephalopathy ; uncorrectable hepatic synthetic dysfunction evince prolongation prothrombin time ascites related portal hypertension ; bacterial fungal liver abscess ; biliary obstruction ; chronic viral hepatitis total serum bilirubin &gt; 3 mg/dL ; symptomatic biliary disease ; Karnofsky score &lt; 70 % adult patient Patient poorly control hypertension multiple antihypertensives Patients current &gt; = grade 2 peripheral neuropathy Patient active bacterial fungal infection unresponsive medical therapy DONOR : Identical twin DONOR : Donors unwilling donate PBSC DONOR : Pregnancy DONOR : Infection HIV DONOR : Inability achieve adequate venous access DONOR : Known allergy GCSF DONOR : Current serious systemic illness DONOR : Failure meet FHCRC criterion stem cell donation DONOR : Age &lt; 12 year DONOR : A positive antidonor cytotoxic crossmatch DONOR : Patient donor pair must homozygous mismatch allele</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>